Cisplatinum/Pemetrexed Versus Split-dose Cisplatinum/Pemetrexed In NSCLC
Status:
Unknown status
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
Cisplatinum and pemetrexed (ALIMTA®) has become an effective first-line regimen for advanced
and inoperable non-squamous NSCLC without somatic activating mutations of epidermal growth
factor receptor (EGFR). In the standard regimen the cisplatinum dose is 75 mg/m2 on day 1 of
a 21-day cycle. Due to the high platinum-dose patients do need a strict hyperhydration and
often have to be hospitalized for survey. Split-dose cisplatinum with two administrations on
Day 1 and 8 of a 21-day-cycle has already been administered in other platin-containing
chemotherapy regimens (cis/gem cis/nav cis/paclitaxel cis/docetaxel) with favourable toxicity
profiles and generally with an excellent patient compliance.